NRX Pharmaceuticals Reports $1.1M Revenue in Q2 2026, Net Loss of $16.5M

NRX Pharmaceuticals, Inc. reported its financial results for the second quarter of 2026, revealing a net patient service revenue of $1.1 million for the three months ended June 30, 2026, and $2.2 million for the six months ended June 30, 2026. This marks a significant milestone for the company, as it had not generated any revenue during the same periods in 2025. The revenue is attributed to the operations of Dura Medical, LLC, which was acquired on September 8, 2025. Despite this revenue generation, the company reported a net loss of $16.5 million for the second quarter, a slight improvement from a net loss of $17.6 million in the same quarter of the previous year.

Operating expenses for the second quarter totaled $7.6 million, up from $3.7 million in the prior year, primarily driven by increased costs associated with patient services, research and development, and general administrative expenses. The cost of patient services was $0.7 million, reflecting the operational costs of Dura, while research and development expenses rose to $2.1 million, up from $1.0 million in the previous year. The increase in general and administrative expenses to $4.7 million from $2.7 million was largely due to higher employee and contractor costs.

In terms of strategic developments, NRX Pharmaceuticals has made significant strides in its drug development pipeline. The company is preparing for the launch of its preservative-free ketamine product, KETAFREE™, expected in the fourth quarter of 2026. Additionally, the company has initiated a New Drug Application (NDA) for NRX-100 and is conducting a trial for NRX-101 in collaboration with the Defense Advanced Research Projects Agency (DARPA). The acquisition of GeNeuro, Inc. has also expanded NRX's portfolio, providing access to investigational antibody products and a substantial patent portfolio.

As of June 30, 2026, NRX Pharmaceuticals reported total assets of $34.2 million, a significant increase from $13.0 million at the end of 2025, primarily due to the acquisition of Dura and the capital raised through public offerings. The company had cash and cash equivalents of $26.7 million, up from $7.8 million at the end of the previous year. However, the company also reported a working capital deficit of $4.7 million and a stockholders' deficit of $0.2 million, raising concerns about its ability to continue as a going concern. Management anticipates ongoing operating losses and plans to pursue additional financing to support its operations and growth initiatives.